<DOC>
	<DOCNO>NCT00422383</DOCNO>
	<brief_summary>This study evaluate efficacy safety various treatment retreatment regimens MabThera . All patient receive concomitant methotrexate , 10-25mg weekly either orally parenterally . The anticipated time study treatment 2+ year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Retreatment With MabThera ( Rituximab ) Combination With Methotrexate Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient &gt; =18 year age ; RA &gt; =6 month ; receive outpatient treatment ; inadequate response methotrexate , receive tolerated &gt; =12 week , stable dose &gt; =4 week . rheumatic autoimmune disease RA , significant systemic involvement secondary RA ; inflammatory joint disease RA , systemic autoimmune disorder ; diagnosis juvenile arthritis , RA age 16 ; previous treatment &gt; 1 biologic agent , celldepleting therapy , concurrent treatment biologic agent DMARD methotrexate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>